| |
|
|
Bivariate analysis |
Multivariate analysis, n =793 |
| |
Occurrence |
Cox |
|
Fine-Gray |
|
Cox |
|
Fine-Gray |
|
| Characteristics |
n =1136 |
% |
HR$crude[80% CI] |
P |
SHR¶crude[80% CI] |
P |
HRajusted[95% CI] |
P * |
SHRajusted[95% CI] |
P * |
Age at Ti **(year) |
|
|
|
0.0048 |
|
0.0013 |
|
0.0264 |
|
0.0058 |
[18 – 50] |
210 |
21.81 |
1(Reference) |
|
1(Reference) |
|
1(Reference) |
|
1(Reference) |
|
[50 – 82] |
55 |
31.79 |
1.53 [1.26–1.86] |
|
1.61 [1.33–1.95] |
|
1.47 [1.04–2.07] |
|
1.60 [1.14–2.25] |
|
Therapeutic education |
|
|
|
<0.0001 |
|
<0.0001 |
|
0.0241 |
|
0.0341 |
No |
202 |
22.20 |
1(Reference) |
|
1(Reference) |
|
1(Reference) |
|
1(Reference) |
|
Yes |
63 |
27.88 |
1.77 [1.47–2.14] |
|
1.57 [1.30–1.90] |
|
1.43 [1.04–1.97] |
|
1.39 [1.02–1.89] |
|
AIDS-defining illness |
N=1092 |
100% |
|
0.0006 |
|
0.0129 |
|
0.0511 |
|
0.1605 |
No |
209 |
22.21 |
1(Reference) |
|
1(Reference) |
|
1(Reference) |
|
1(Reference) |
|
Yes |
47 |
31.13 |
1.74 [1.41–2.14] |
|
1.50 [1.21–1.86] |
|
1.45 [0.99–2.10] |
|
1.31 [0.89–1.92] |
|
VL (log10 copie/mm3) Ti ** |
N=829 |
100% |
|
0.0216 |
|
0.0173 |
|
0.0392 |
|
0.0308 |
[1.7– 4.0] |
32 |
16.75 |
1(Reference) |
|
1(Reference) |
|
1(Reference) |
|
1(Reference) |
|
[4.0– 5.0] |
86 |
26.71 |
1.74 [1.33–2.27] |
|
1.75 [1.35–2.28] |
|
1.71 [1.12–2.60] |
|
1.73 [1.15–2.60] |
|
≥ 5.0 |
79 |
25.00 |
1.66 [1.26–2.17] |
|
1.66 [1.27–2.17] |
|
1.41 [0.91–2.18] |
|
1.48 [0.97–2.26] |
|
* P-value obtained by backward stepwise regression
** Ti : Time of HAART initiation
$ Hazard Ratio obtained by Cox model
¶ Subdistribution Hazards Ratio obtained by Fine-Gray model |
